FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3189569397> ?p ?o ?g. }

• W3189569397 endingPage "641" @default.
• W3189569397 startingPage "633" @default.
• W3189569397 abstract "Background Dupilumab is an antibody against interleukin-4 receptor α, used in the treatment of atopic dermatitis (AD). Objectives To evaluate the efficacy and safety of dupilumab in adult Chinese patients with moderate-to-severe AD. Methods In this randomized, double-blind, placebo-controlled, parallel-group, phase III study, conducted between December 2018 and February 2020, patients with AD received dupilumab (300 mg) or placebo once every 2 weeks for 16 weeks, and were followed up for 12 weeks. The primary efficacy endpoint was the proportion of patients with both an Investigator’s Global Assessment score of 0–1 and a reduction from baseline of ≥ 2 points at week 16. Results Overall, 165 patients (mean age 30·6 years; 71·5% male patients) were randomized; 82 patients were randomized to dupilumab and 83 patients were randomized to placebo. At week 16, 26·8% of patients in the dupilumab group and 4·8% of patients in the placebo group achieved the primary endpoint [difference 22·0%, 95% confidence interval (CI) 11·37–32·65; P < 0·001]. Compared with placebo, higher proportions of patients in the dupilumab group achieved ≥ 75% reduction in the Eczema Area and Severity Index score (57·3% vs. 14·5%; difference 42·9%, 95% CI 29·75–55·97; P < 0·001) and had ≥ 3-point (52·4% vs. 9·6%; difference 42·8%, 95% CI 30·26–55·34; P < 0·001) and ≥ 4-point (39·0% vs. 4·8%; difference 34·2%, 95% CI 22·69–45·72; P < 0·001) reductions in weekly average daily peak daily pruritus numerical rating scale scores. The incidence of treatment-emergent adverse events during the treatment period was similar in the two groups. The incidence of conjunctivitis, allergic conjunctivitis and injection site reaction was higher in the dupilumab group than in the placebo group. Conclusions In adult Chinese patients, dupilumab was effective in improving the signs and symptoms of AD and demonstrated a favourable safety profile." @default.
• W3189569397 created "2021-08-16" @default.
• W3189569397 creator A5009048013 @default.
• W3189569397 creator A5011241116 @default.
• W3189569397 creator A5015189970 @default.
• W3189569397 creator A5017155583 @default.
• W3189569397 creator A5021500184 @default.
• W3189569397 creator A5022140000 @default.
• W3189569397 creator A5022343550 @default.
• W3189569397 creator A5023283416 @default.
• W3189569397 creator A5024338340 @default.
• W3189569397 creator A5028474331 @default.
• W3189569397 creator A5029118314 @default.
• W3189569397 creator A5029947113 @default.
• W3189569397 creator A5030360317 @default.
• W3189569397 creator A5040758734 @default.
• W3189569397 creator A5045902636 @default.
• W3189569397 creator A5058714794 @default.
• W3189569397 creator A5063865747 @default.
• W3189569397 creator A5065563933 @default.
• W3189569397 creator A5068371488 @default.
• W3189569397 creator A5070374842 @default.
• W3189569397 creator A5072516184 @default.
• W3189569397 creator A5072622243 @default.
• W3189569397 creator A5075399042 @default.
• W3189569397 creator A5075440559 @default.
• W3189569397 creator A5078047572 @default.
• W3189569397 creator A5078646891 @default.
• W3189569397 creator A5078653336 @default.
• W3189569397 creator A5081702651 @default.
• W3189569397 creator A5083238917 @default.
• W3189569397 creator A5085812346 @default.
• W3189569397 creator A5087121113 @default.
• W3189569397 creator A5089498872 @default.
• W3189569397 date "2021-10-21" @default.
• W3189569397 modified "2023-10-15" @default.
• W3189569397 title "The efficacy and safety of dupilumab in Chinese patients with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled study*" @default.
• W3189569397 cites W1858234123 @default.
• W3189569397 cites W2117983771 @default.
• W3189569397 cites W2118862186 @default.
• W3189569397 cites W2524051065 @default.
• W3189569397 cites W2566687596 @default.
• W3189569397 cites W2610814011 @default.
• W3189569397 cites W2791135802 @default.
• W3189569397 cites W2899071879 @default.
• W3189569397 cites W2900959710 @default.
• W3189569397 cites W2940853643 @default.
• W3189569397 cites W2976798343 @default.
• W3189569397 cites W2981609698 @default.
• W3189569397 cites W2999975900 @default.
• W3189569397 cites W3029347445 @default.
• W3189569397 cites W3036352764 @default.
• W3189569397 cites W3037902116 @default.
• W3189569397 cites W3087016166 @default.
• W3189569397 doi "https://doi.org/10.1111/bjd.20690" @default.
• W3189569397 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34358343" @default.
• W3189569397 hasPublicationYear "2021" @default.
• W3189569397 type Work @default.
• W3189569397 sameAs 3189569397 @default.
• W3189569397 citedByCount "17" @default.
• W3189569397 countsByYear W31895693972022 @default.
• W3189569397 countsByYear W31895693972023 @default.
• W3189569397 crossrefType "journal-article" @default.
• W3189569397 hasAuthorship W3189569397A5009048013 @default.
• W3189569397 hasAuthorship W3189569397A5011241116 @default.
• W3189569397 hasAuthorship W3189569397A5015189970 @default.
• W3189569397 hasAuthorship W3189569397A5017155583 @default.
• W3189569397 hasAuthorship W3189569397A5021500184 @default.
• W3189569397 hasAuthorship W3189569397A5022140000 @default.
• W3189569397 hasAuthorship W3189569397A5022343550 @default.
• W3189569397 hasAuthorship W3189569397A5023283416 @default.
• W3189569397 hasAuthorship W3189569397A5024338340 @default.
• W3189569397 hasAuthorship W3189569397A5028474331 @default.
• W3189569397 hasAuthorship W3189569397A5029118314 @default.
• W3189569397 hasAuthorship W3189569397A5029947113 @default.
• W3189569397 hasAuthorship W3189569397A5030360317 @default.
• W3189569397 hasAuthorship W3189569397A5040758734 @default.
• W3189569397 hasAuthorship W3189569397A5045902636 @default.
• W3189569397 hasAuthorship W3189569397A5058714794 @default.
• W3189569397 hasAuthorship W3189569397A5063865747 @default.
• W3189569397 hasAuthorship W3189569397A5065563933 @default.
• W3189569397 hasAuthorship W3189569397A5068371488 @default.
• W3189569397 hasAuthorship W3189569397A5070374842 @default.
• W3189569397 hasAuthorship W3189569397A5072516184 @default.
• W3189569397 hasAuthorship W3189569397A5072622243 @default.
• W3189569397 hasAuthorship W3189569397A5075399042 @default.
• W3189569397 hasAuthorship W3189569397A5075440559 @default.
• W3189569397 hasAuthorship W3189569397A5078047572 @default.
• W3189569397 hasAuthorship W3189569397A5078646891 @default.
• W3189569397 hasAuthorship W3189569397A5078653336 @default.
• W3189569397 hasAuthorship W3189569397A5081702651 @default.
• W3189569397 hasAuthorship W3189569397A5083238917 @default.
• W3189569397 hasAuthorship W3189569397A5085812346 @default.
• W3189569397 hasAuthorship W3189569397A5087121113 @default.
• W3189569397 hasAuthorship W3189569397A5089498872 @default.
• W3189569397 hasBestOaLocation W31895693971 @default.
• W3189569397 hasConcept C126322002 @default.
• W3189569397 hasConcept C142724271 @default.

• next